Cargando…

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

PURPOSE: Lorlatinib is a third-generation tyrosine kinase inhibitor currently approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. This open-label, phase 1, randomized two-sequence, two-treatment, two-period, crossover study investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933379/ https://www.ncbi.nlm.nih.gov/pubmed/34698901 http://dx.doi.org/10.1007/s00280-021-04368-1

Ejemplares similares

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2022)

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
por: Chen, Joseph, et al.
Publicado: (2021)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
por: Testa, Stefano, et al.
Publicado: (2021)

Lymphomatous Meningitis From Anaplastic Lymphoma Kinase+ Anaplastic Large T-Cell Lymphoma Treated With Lorlatinib: A Case Report
por: Mellacheruvu, Smitha, et al.
Publicado: (2022)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
por: Li, Jerry, et al.
Publicado: (2021)

4558 Investigating the functional consequences of anaplastic lymphoma kinase (ALK) mutations arising upon Lorlatinib treatment
por: Witek, Gabriela Maria, et al.
Publicado: (2020)

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants
por: Chen, Joseph, et al.
Publicado: (2021)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
por: Gourzoulidis, George, et al.
Publicado: (2022)

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
por: Liang, Shuai, et al.
Publicado: (2021)

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
por: Presa, María, et al.
Publicado: (2023)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
por: Li, SiNi, et al.
Publicado: (2021)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
por: Naik, Jaesh, et al.
Publicado: (2023)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
por: Ucpinar, Sibel, et al.
Publicado: (2023)

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report
por: Wang, Huan, et al.
Publicado: (2023)

Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation
por: Patil, Keshav, et al.
Publicado: (2021)

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
por: Nilsson, Fredrik O. L., et al.
Publicado: (2021)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
por: Kashizaki, Fumihiro, et al.
Publicado: (2022)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase in Cutaneous Malignancies
por: Cao, Severine, et al.
Publicado: (2017)

Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age
por: Ke, Li, et al.
Publicado: (2018)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments
por: Latif, Muhammad, et al.
Publicado: (2018)

Novel High-Throughput Microwell Spectrophotometric Assay for One-Step Determination of Lorlatinib, a Novel Potent Drug for the Treatment of Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer
por: Al-Hossaini, Abdullah M., et al.
Publicado: (2023)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Anaplastic lymphoma kinase: signalling in development and disease
por: Palmer, Ruth H., et al.
Publicado: (2009)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

The role of anaplastic lymphoma kinase in pediatric cancers
por: Takita, Junko
Publicado: (2017)

Anaplastic lymphoma kinase inhibitor-associated myositis
por: Uruha, Akinori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_61b19l4jpsi90u701trjluq29n